As of 2026-04-05, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -93.41. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 496.38 mil USD. TBPH's TTM EBITDA according to its financial statements is -5.31 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 5.6x - 7.4x | 6.6x |
| Forward P/E multiples | 9.1x - 10.5x | 9.9x |
| Fair Price | 5.64 - 16.83 | 10.88 |
| Upside | -64.8% - 5.1% | -32.1% |
| Date | EV/EBITDA |
| 2026-03-30 | -86.16 |
| 2026-03-27 | -84.45 |
| 2026-03-26 | -85.49 |
| 2026-03-25 | -86.45 |
| 2026-03-24 | -82.73 |
| 2026-03-23 | -81.30 |
| 2026-03-20 | -77.29 |
| 2026-03-19 | -74.24 |
| 2026-03-18 | -72.53 |
| 2026-03-17 | -73.39 |
| 2026-03-16 | -73.48 |
| 2026-03-13 | -72.05 |
| 2026-03-12 | -73.10 |
| 2026-03-11 | -72.34 |
| 2026-03-10 | -74.43 |
| 2026-03-09 | -74.15 |
| 2026-03-06 | -70.05 |
| 2026-03-05 | -70.14 |
| 2026-03-04 | -70.95 |
| 2026-03-03 | -73.77 |
| 2026-03-02 | -121.35 |
| 2026-02-27 | -114.67 |
| 2026-02-26 | -114.10 |
| 2026-02-25 | -122.40 |
| 2026-02-24 | -122.40 |
| 2026-02-23 | -124.30 |
| 2026-02-20 | -128.12 |
| 2026-02-19 | -125.92 |
| 2026-02-18 | -123.45 |
| 2026-02-17 | -120.01 |
| 2026-02-13 | -126.88 |
| 2026-02-12 | -125.64 |
| 2026-02-11 | -126.69 |
| 2026-02-10 | -125.64 |
| 2026-02-09 | -126.59 |
| 2026-02-06 | -135.94 |
| 2026-02-05 | -127.35 |
| 2026-02-04 | -132.22 |
| 2026-02-03 | -131.26 |
| 2026-02-02 | -129.74 |
| 2026-01-30 | -121.25 |
| 2026-01-29 | -123.54 |
| 2026-01-28 | -122.11 |
| 2026-01-27 | -129.64 |
| 2026-01-26 | -128.98 |
| 2026-01-23 | -133.65 |
| 2026-01-22 | -138.42 |
| 2026-01-21 | -134.89 |
| 2026-01-20 | -135.36 |
| 2026-01-16 | -131.45 |